Nasal Spray Flu Vaccine No Problem for Kids With Asthma
(MedPage Today) -- The intranasal live attenuated flu vaccine is just as safe for children with asthma as the intramuscular inactivated vaccine, a small clinical trial suggested.
Within 42 days of vaccination, 10.8% of children who received the... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 28, 2022 Category: Allergy & Immunology Source Type: news
Military Exposure to Burn Pits Under Scrutiny
(MedPage Today) -- Doctors, scientists, and patient advocates described the tremendous harms of burn pits to active duty service members and veterans, ranging from cancers to severe respiratory illness and death, during a hearing of the Senate... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 17, 2022 Category: Allergy & Immunology Source Type: news
Antisense Drug Slashed Hereditary Angioedema Attacks in Small Study
(MedPage Today) -- Patients with hereditary angioedema who were treated with an antisense oligonucleotide treatment, donidalorsen, experienced significantly fewer attacks than patients who received placebo, a phase II trial showed.
Over 17 weeks... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 16, 2022 Category: Allergy & Immunology Source Type: news
First Generic OK'd for Popular Asthma, COPD Inhaler
(MedPage Today) -- The first generic version of Symbicort -- a metered-dose inhaler that combines the corticosteroid budesonide with the long-acting bronchodilator formoterol -- has been approved for asthma and chronic obstructive pulmonary... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 15, 2022 Category: Allergy & Immunology Source Type: news
First Drug-Eluting Contact Lens Wins FDA Nod
(MedPage Today) -- A drug-eluting contact lens containing an antihistamine for people with allergic eye itch won approval from the FDA, Johnson & Johnson Vision Care announced.
The daily disposable etafilcon A drug-eluting contact lens with... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 3, 2022 Category: Allergy & Immunology Source Type: news
Mepolizumab Reduces Need for Oral Steroids in Severe Asthma
(MedPage Today) -- PHOENIX -- Treatment with the interleukin-5 (IL-5) antagonist mepolizumab (Nucala) reduced the need to take oral corticosteroids by 75% in patients who had depended on the steroids to control symptoms of severe asthma, a researcher... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 2, 2022 Category: Allergy & Immunology Source Type: news
Docs Debate Home Spirometry
(MedPage Today) -- PHOENIX -- Experts in lung diseases debated at the annual meeting of the American Academy of Allergy, Asthma & Immunology here whether at-home spirometry tests and devices, which are now available from multiple companies... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 2, 2022 Category: Allergy & Immunology Source Type: news
Does One Mab Come Out on Top for Boosting Lung Function in Asthma?
(MedPage Today) -- PHOENIX -- In some patients with eosinophilic asthma, dupilumab (Dupixent) offered the highest chance of better lung function, although the agent also carried the highest odds of serious adverse events (AEs), a researcher reported... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 1, 2022 Category: Allergy & Immunology Source Type: news
Kids With Acute Respiratory Failure See Lower IQ Scores Later On
(MedPage Today) -- Children who received mechanical ventilation at a pediatric intensive care unit (PICU) had slightly worse cognitive outcomes in the long run compared with their siblings, a prospective cohort study found.
At 3 to 8 years after... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 1, 2022 Category: Allergy & Immunology Source Type: news
Mepolizumab Cuts Asthma Flare-Ups in Disadvantaged Kids
(MedPage Today) -- PHOENIX -- Adding mepolizumab (Nucala) to guideline-based care reduced flare-ups in disadvantaged kids with exacerbation-prone, eosinophilic asthma, the yearlong MUPPITS-2 trial showed.
In the randomized study of nearly 300... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 1, 2022 Category: Allergy & Immunology Source Type: news
Many Severe Asthma Patients Achieve Remission on Biologics
(MedPage Today) -- PHOENIX -- Biologic medications sent severe asthma into remission in a substantial proportion of patients, according to a study presented here at the annual meeting of the American Academy of Allergy, Asthma & Immunology... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 28, 2022 Category: Allergy & Immunology Source Type: news
Tezepelumab Benefits Asthma Patients Year-Round
(MedPage Today) -- PHOENIX -- Patients with severe, uncontrolled asthma experienced greater relief throughout the year when treated with the biologic tezepelumab (Tezspire) versus placebo, according to findings from the phase III NAVIGATOR study... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 28, 2022 Category: Allergy & Immunology Source Type: news
Medical Approach May Work in Nasal Polyps With Asthma
(MedPage Today) -- PHOENIX – Patients who have nasal polyps appeared to get symptom relief when treated with omalizumab (Xolair) regardless of comorbid asthma, according to a post-hoc trial analysis.
All patients taking omalizumab achieved... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 28, 2022 Category: Allergy & Immunology Source Type: news
Glimpses of Hope for Lebrikizumab in Asthma
(MedPage Today) -- PHOENIX -- Exacerbation-prone asthma patients who had high blood eosinophil counts or elevated fractional exhaled nitric oxide (FeNO) appeared to benefit from lebrikizumab, pooled data from two disappointing phase III trials... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 28, 2022 Category: Allergy & Immunology Source Type: news
One Nutty Gene: Peanut Oral Immunotherapy Outcomes Affected by HLA Allele
(MedPage Today) -- PHOENIX -- An immune system gene variant may affect outcomes with oral immunotherapy treatments (OITs) for peanut allergies, an analysis of three different clinical trials showed.
In the IMPACT study, toddlers ages 12 to ... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 28, 2022 Category: Allergy & Immunology Source Type: news
